NASDAQ:GYRE

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Gyre Therapeutics logo
$4.34 -0.22 (-4.82%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$4.42 +0.08 (+1.73%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Gyre Therapeutics Stock (NASDAQ:GYRE)

Advanced

Key Stats

Today's Range
$4.34
▼
$4.72
50-Day Range
$4.01
▼
$7.55
52-Week Range
$3.97
▼
$9.14
Volume
466,619 shs
Average Volume
226,525 shs
Market Capitalization
$500.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals.

Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.

AI Generated. May Contain Errors.

Gyre Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

GYRE MarketRank™: 
0.58904109589 of 5 stars

Gyre Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 1635th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gyre Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Gyre Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Gyre Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Gyre Therapeutics are expected to decrease in the coming year, from ($0.34) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gyre Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gyre Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gyre Therapeutics has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.22% of the float of Gyre Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gyre Therapeutics has a short interest ratio ("days to cover") of 14.22, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Gyre Therapeutics has recently increased by 16.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Gyre Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gyre Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Gyre Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Gyre Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for GYRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Gyre Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.50% of the stock of Gyre Therapeutics is held by insiders.

  • Percentage Held by Institutions

    23.99% of the stock of Gyre Therapeutics is held by institutions.

  • Read more about Gyre Therapeutics' insider trading history.
Receive GYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GYRE Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Headlines

GYRE Stock Analysis - Frequently Asked Questions

Gyre Therapeutics' stock was trading at $7.06 at the start of the year. Since then, GYRE stock has decreased by 38.5% and is now trading at $4.34.

Gyre Therapeutics, Inc. (NASDAQ:GYRE) announced its earnings results on Thursday, November, 5th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.19. The business earned $32.93 million during the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative trailing twelve-month return on equity of 7.39% and a negative net margin of 14.80%.

Top institutional investors of Gyre Therapeutics include State Street Corp (0.21%), SBI Securities Co. Ltd. (0.15%) and Goldman Sachs Group Inc. (0.05%). Insiders that own company stock include Songjiang Ma, Ying Luo, Weiguo Ye and Nassim Usman.
View institutional ownership trends
.

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:GYRE
Previous Symbol
NASDAQ:GYRE
CIK
1124105
Employees
618
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$5.03 million
Net Margins
-14.80%
Pretax Margin
-13.60%
Return on Equity
-7.39%
Return on Assets
-5.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.32
Quick Ratio
3.89

Sales & Book Value

Annual Sales
$116.59 million
Price / Sales
4.29
Cash Flow
$0.21 per share
Price / Cash Flow
20.52
Book Value
$1.25 per share
Price / Book
3.47

Miscellaneous

Outstanding Shares
115,320,000
Free Float
104,366,000
Market Cap
$500.49 million
Optionable
Optionable
Beta
2.14
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:GYRE) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners